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Summary 
 
Background and purpose: It has been proposed that BRL37344, SR58611 and 
CGP12177 activate β3-adrenoceptors (β3AR) in human atrium to increase contractility 
and L-type Ca2+ current (ICa-L). β3AR agonists are potentially beneficial for the 
treatment of a variety of diseases but concomitant cardiostimulation would be 
potentially harmful. It has also been proposed that (-)-CGP12177 activates the low 
affinity binding site of the β1AR in human atrium. We therefore used BRL37344 
SR58611 and (-)-CGP12177 with selective βAR subtype antagonists to clarify 
cardiostimulant βAR subtypes in human atrium. 
 
Experimental approach: Human right atrium was obtained from patients without heart 
failure undergoing coronary artery bypass or valve surgery. Cardiomyocytes were 
prepared to test BRL37344, SR58611 and CGP12177 effects on ICa-L. Contractile effects 
were determined on right atrial trabeculae.  
 
Key results: BRL37344 increased force which was antagonized by blockade of 
β1AR/β2AR but not by blockade of β3AR with β3AR-selective L-748,337 (1μM). The 
β3AR agonist SR58611 (1nM-10μM) did not affect atrial force. BRL37344 and 
SR58611 did not increase ICa-L at 37°C, but did at 24°C which was prevented by L-
748,337. (-)-CGP12177 increased force and ICa-L at both 24°C and 37°C which was 
prevented by (-)-bupranolol (1-10μM), but not L-748,337.  
 
Conclusions and implications: We conclude that the inotropic responses to BRL37344 
are mediated through β1AR/β2AR. The inotropic and ICa-L responses to (-)-CGP12177 
are mediated through the low affinity site β1LAR of the β1AR. β3AR-mediated increases 
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in ICa-L are restricted to low temperatures. Human atrial β3AR do not change 
contractility and ICa-L at physiological temperature.  
 
Key words: Human atrial force and ICa-L, (-)-CGP 12177, β1L-adrenoceptors, β3-
adrenoceptors, L-748,337, BRL37344, SR58611, (-)-bupranolol  
 
Abbreviations: βAR, β-adrenoceptor; β1AR, β1-adrenoceptor; β1LAR, low affinity β1-
adrenoceptor; β1HAR, high affinity β1-adrenoceptor; β2AR, β2-adrenoceptor;  β3AR, β3-
adrenoceptor; BRL37344, (RR+SS)[4-[2-[[2-(3-chlorophenyl)-2-hydroxy-
ethyl]amino]propyl]phenoxy]acetic acid; (-)-CGP 12177, (7)-4-(3-tertiarybutylamino-2-
hydroxypropoxy) benzimidazol-2-one; IBMX, 3-isobutyl-1-methylxanthine; ICa-L, L-
type Ca2+ current; ICI118,551, 1-[2,3-dihydro-7-methyl-1H-inden-4-yl] oxy-3-                 
[(1-methylethyl)amino-2-butanol);] PDE, phosphodiesterase enzyme; L-748,337 N-(3-
[3-[2-(4-benzenesulphonylaminophenyl)ethylamino]-2-hydroxypropoxy]benzyl 
acetamide; PKA, cAMP-dependent protein kinase; SR58611, ethyl{(7S)-7-[(2R)-2-(3-
chlorophenyl)-2-hydroxyethylamino]-5,6,7,8-tetrahydronaphtyl2-yloxy}acetate 
hydrochloride 
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Introduction 
 
There is evidence that β3-adrenoceptors (β3AR) are expressed in human heart (Krief et 
al., 1993; Moniotte et al., 2001a;b) but the relevance to contractile function is 
controversial. Agonists for β3AR have been reported to cause cardiodepressant effects 
on human ventricle obtained from endomyocardial biopsies (Gauthier et al., 1996; 
Rozec et al., 2006), possibly by release of nitric oxide from endothelial and/or 
endocardial cells. In contrast, β3AR agonists did not produce cardiostimulant or 
depressant effects in human ventricular trabeculae (Molenaar et al., 1997; Kaumann and 
Molenaar, 2008) or human ventricular myocytes (Harding, 1997). However, Napp et al. 
(2009) recently reported a negative inotropic effect of BRL37344 that was prevented by 
the NO antagonist L-NMA. We have previously reported that β3AR agonists are 
devoid of cardiostimulant or cardiodepressant effects in human atrium in the presence of 
(-)-propranolol (200 nM) (Kaumann et al., 1997), a concentration that antagonizes the 
effects of (-)-noradrenaline and (-)-adrenaline through human atrial β1AR and β2AR 
(Gille et al., 1985) but is not expected to block β3AR (Cohen et al., 1999; Hoffmann et 
al., 2004). Modest cardiostimulant effects of additional β3AR agonists (Sennitt et al., 
1998), including BRL37344 (Arch and Kaumann, 1993; Pott et al., 2003), were 
antagonized by (-)-propranolol (200-300 nM), consistent with their mediation through 
β1AR and β2AR but not β3AR. Taken together, the information published is inconsistent 
with regard to a cardiostimulant or cardiodepressant role of human atrial β3AR. 
 
Some β-blockers with high affinity for both β1AR and β2AR cause cardiostimulation at 
concentrations considerably greater than those needed to significantly antagonize the 
effects of catecholamines. Their agonist effects are smaller and more resistant to 
antagonism by β-blockers (e.g. propranolol, nadolol, (Kaumann and Molenaar, 2008)) 
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than the effects of catecholamines. Accumulating evidence from cardiac and 
recombinant receptors indicates that these non-conventional partial agonists induce their 
agonist effects through a β1-adrenoceptor site (β1LAR) for which they have lower 
affinity than for the site (β1HAR) through which they antagonize the effects of 
catecholamines (reviewed, Kaumann and Molenaar, 2008). The hydrophilic compound 
CGP12177, introduced as a high-affinity βAR radioligand by Staehelin et al. (1983) and 
soon thereafter discovered to exert cardiostimulant properties (Kaumann, 1983), has 
since been extensively used as an experimental non-conventional partial agonist 
(Kaumann and Molenaar, 2008). The cardiostimulant effects of (-)-CGP12177, 
mediated through β1LAR, are antagonized by (-)-bupranolol (Kaumann and Molenaar, 
2008). Although CGP12177 does bind to β3AR (Cohen et al., 1999; Hoffmann et al., 
2004), it is only a weak lipolytic partial agonist in murine adipocytes (Preitner et al., 
1998) through β3AR but not in human adipocytes (Tavernier et al., 1996), and there is 
no evidence that its cardiostimulant effects are mediated through β3AR (Cohen et al., 
1999; Kaumann and Molenaar, 2008). However, when human β3AR are overexpressed 
in the murine heart they mediate cardiostimulation (Kohout et al., 2001). 
 
Surprisingly, Skeberdis et al. (2008) recently postulated that β3ARs mediate increases in 
human atrial contractility. They demonstrated, in human atrial myocytes at room 
temperature, that the agonists BRL37344, SR58611 and CGP12177 increase the L-type 
Ca2+ current (ICa-L) and these responses were reversed by the β3AR-selective antagonist 
L-748,337 (Candelore et al., 1999). They reported agonist-evoked increases in 
contractility of atrial tissues at 37ºC. Theses modest human atrial responses to 
CGP12177 (Kaumann, 2006; Skeberdis et al., 2008) can be enhanced by the non-
selective phosphodiesterase (PDE) inhibitor 3-isobutyl-1-methylxanthine (IBMX) 
 6
(Kaumann and Molenaar, 1997) and PDE3 inhibitor cilostamide (Kaumann et al., 
2007). In addition, Skeberdis et al. (2008) observed marked increases in the contractile 
responses to CGP12177 and BRL37344 in the presence of IBMX in human atrium at 
37°C. Importantly, however, they did not investigate whether these effects could be 
antagonized by L-748,337, as one would expect from an interaction through β3AR.  
 
Activation of β3AR has been proven as a therapeutic target for the treatment of 
overactive bladder disorder (Yamaguchi, 2002; Chapple et al., 2008; Michel et al., 
2010), and could plausibly be beneficial in type 2 diabetes (Sawa and Harada, 2006; 
Arch, 2008) as well as for disorders such as anxiety and depression (Stemmelin et al., 
2008). However, if human atrial β3ARs mediate cardiostimulation, this could be 
associated with tachycardia and potentially deleterious arrhythmias, including atrial 
fibrillation, thus limiting or even excluding their use in humans. Further research is 
therefore needed to confirm whether or not β3ARs mediate an increase in human atrial 
contractility. 
 
The study done by Skeberdis et al. (2008) also challenges the concept that the positive 
inotropic effects of CGP12177 and other non-conventional partial agonists on human 
atrial myocardium are mediated through β1LAR (Joseph et al., 2003; Sarsero et al., 
2003; Kaumann and Molenaar, 2008). We previously found in human atrial trabeculae 
that L-748,337 failed to antagonize the positive inotropic effects of the non-
conventional partial agonist (-)-pindolol, mediated through β1LAR, as confirmed with 
recombinant β1AR (Joseph et al., 2003). Our aim was therefore to investigate, using 
IBMX, whether L-748,337 could antagonize the inotropic effects of BRL37344, 
SR58611 and (-)-CGP12177 on human atrial preparations at 37°C. However, we did not 
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observe inotropic effects with SR58611. To investigate whether different receptors 
could be activated by BRL37344, SR58611 and (-)-CGP12177 as a function of 
temperature, we compared their ICa-L responses at 24°C and 37°C. Also, to investigate 
whether the ICa-L responses to the agonists at 24°C couple to atrial contractile force, we 
also determined their effects on contractile force at 24°C. 
 
 
Methods 
 
 
Patients  
 
Right atrial appendages were obtained from patients undergoing coronary artery bypass 
surgery at The Prince Charles Hospital, Brisbane, who had provided written informed 
consent (The Prince Charles Hospital Ethics Committee EC27133; QUT human ethics 
committee 0800000066) and Dresden University of Technology (Medical Faculty 
Ethics committee document EK790799). Patient characteristics are outlined in Table 1. 
 
Contractility studies 
After excision, the appendages for the experiments of Figures 1, 3 and 4 (carried out in 
Brisbane) were immediately placed in modified oxygenated ice-cold Krebs solution 
containing (mM): Na+ 125, K+ 5, Ca2+ 2.25, Mg2+ 0.5, Cl− 98.5, SO42- 0.5, HCO3- 34, 
HPO42- 1, ethylenediaminetetraacetic acid 0.04, and equilibrated with 95% O2/5% CO2. 
Trabeculae were dissected and set up, on occasion, in pairs to contract at 1 Hz in an 
apparatus with a 50-ml organ bath in the solution above supplemented with (mM): Na+ 
15, fumarate 5, pyruvate 5, L-glutamate 5, glucose 10 at 37°C, as described (Gille et al., 
1985; Molenaar et al., 2007). The tissues were attached to Swema SG4-45 strain gauge 
transducers and force recorded on a Watanabe polygraph. The tissues were driven with 
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square-wave pulses of 5 ms duration and just over threshold voltage. After 
determination of a length–tension curve, the length of each trabeculum was set to obtain 
50% of the resting tension associated with maximum developed force.  
 
Experiments depicted in Figures 2 and 8 were performed in Tyrode’s solution (mM): 
Na+ 149.12, K+ 5.4, Ca2+ 1.8, Mg2+ 1.05, Cl− 137.8, HCO3- 22, HPO4-- 0.42, 
ethylenediaminetetraacetic acid 0.04, and equilibrated with 95% O2/5% CO2. 
 
The conditions of Skeberdis et al. (2008) were used. Experiments were carried out in the 
presence of nadolol (200 nM), a concentration expected to block both β1HAR and β2AR 
but hardly affect β3AR (pKD=6.2, Baker, 2005) or β1LAR (pKB=6.2, Joseph et al., 
2004), and IBMX (10 μM) to boost the response to (-)-CGP12177 (Kaumann and 
Molenaar, 1997; Kaumann et al., 2007).  
 
Protocols 
Cumulative concentration-effect curves for BRL37344 and SR58611 were carried out in 
the absence and presence of L-748,337 (1 μM). Tissues were pre-incubated with L-
748,337 for 15 min before the addition of nadolol (200 nM), followed by the 
administration of IBMX (10 μM) 30 min later, and finally the curve for an agonist 
begun 15 min later. At least 2 trabeculae from each patient were used and curves for (-)-
CGP12177 in the absence and presence of L-748,337 were time-matched. In other 
experiments concentration-effect curves for BRL37344 were carried out in the absence 
or presence of nadolol (200 nM), ICI118,551 (50 nM) or CGP20712A (300 nM) or the 
combination of ICI118,551 and CGP20712A, in the presence of IBMX (10 μM). The 
effects of BRL37344 are expressed as function of the response to (-)-isoprenaline (200 
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μM), administered after the highest concentration of BRL37344. Some experiments 
were carried out at 24ºC and results with the agonists expressed as % changes of the 
response to IBMX in order to more easily detect small changes. 
 
Kinetic experiments were used to investigate the influence of L-748,337 on the 
contractile responses to (-)-CGP12177. When 4 or more atrial trabeculae were available, 
a time-matched procedure was used comprising 4 experimental groups (as shown in the 
representative experiment of Figure 3A). Trabeculae were incubated with IBMX (10 
μM), which remained in contact with the trabeculae for the remainder of the 
experiment. By the 30th min, 3 groups of trabeculae were incubated with (-)-CGP12177 
(200 nM). Twenty minutes later, upon establishment of the cardiostimulant effect of (-)-
CGP 12177 one group received L-748,337 (1 μM), another received (-)-bupranolol (1 
μM), while the third group was used as a time-matched control to establish the time-
course of the cardiostimulant effect of (-)-CGP 12177. 
 
All experiments were concluded by the administration of a receptor-saturating 
concentration of (-)-isoprenaline (200 μM) and, after an equilibrium response to (-)-
isoprenaline was established, by raising the Ca2+ concentration to 9.25 mM (total bath 
concentration).  
 
Measurements of ICa-L 
 
Human atrial myocytes were enzymatically dissociated as described previously (Christ 
et al., 2001). Myocytes were stored at room temperature until use in a solution 
containing (mM): K+ 100, Cl- 20, H2PO42- 10, glutamic acid 70, taurine 10, β-
hydroxybutyrate 10,  EGTA 10, HEPES 10, albumin 1%, glucose 10, pH 7.4. The single 
electrode patch clamp technique was used to measure ICa-L at 37°C. Holding potential 
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was -80 mV. The K+ currents were blocked by replacing K+ with Cs+. The external 
perfusing solution contained (mM): tetraethylammonium 120, Cs+ 10, Ca2+ 2, Mg2+ 1, 
Cl- 136, HEPES 10 and glucose 10 with pH adjusted with CsOH. The pipette solution 
contained (mM): Cs+ 110, Ca2+ 3, Mg2+ 4, Cl- 26, methanesulphonate- 90, HEPES 10, 
ATP 4, Tris-GTP 0.4 and EGTA 10 with a calculated free Ca2+ concentration of 60 nM 
(EQCAL, Biosoft, Cambridge, UK) and pH 7.2, adjusted with CsOH. Current amplitude 
was determined as the difference between peak inward current and current at the end of 
the 200 ms depolarizing step to +10 mV from a holding potential of -80 mV. Myocytes 
were exposed only once to the different agonists in the absence or presence of IBMX 
(10 µM), nadolol (200 nM), L-748,337 (1 µM), ICI118,551 (50 nM) or (-)-bupranolol 
(10 µM). 
 
Statistics and assessment of antagonism 
Results from the kinetic experiments are expressed in mN force. The –logEC50M values 
for BRL37344 and (-)-CGP12177 in the absence and presence of L-748,337 were 
calculated from the corresponding curves. Data comparisons were made with ANOVA 
and non-paired or paired t-tests as appropriate using GraphPad Prism®. Expected 
concentration ratios (CR) of BRL37344 in the presence and absence of an antagonist 
concentration ([B]) were calculated from CR = 1 + [B]/KB, where KB is the equilibrium 
dissociation constant. Results are presented as mean±SEM, where n values refer to the 
number of trabeculae or myocytes. 
 
Drugs 
 (-)-CGP12177 was a gift from Dr Jonathan Arch (GlaxoSmithKline, Harlow, UK), (-)-
bupranolol was a gift from Dr Klaus Sandrock (Sanol-Schwarz, Monheim, Germany), 
SR58611 was a gift from Dr Luciano Manara (Sanofi, Milan, Italy); L-748,337 was 
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from Tocris (Bristol, UK), BRL37344 was from Tocris (Bristol, UK) or Sigma (Castle 
Hill, Australia). IBMX and (-)-isoprenaline hydrochloride were from Sigma (Castle 
Hill, Australia or Poole Dorset, UK).  
 
 
Results  
 
Antagonism of the inotropic effects of BRL37344 by βAR subtype-selective antagonists 
in  atrial trabeculae.  
To reduce cAMP hydrolysis and enhance inotropic responses, experiments were carried 
out in the presence of the non-selective PDE inhibitor IBMX (10 μM).  IBMX increased 
force from 5.86±0.50 mN to 8.70±0.70 mN (n=116 trabeculae from 29 patients) (Figure 
1, 2A and 4). There was no difference between the groups represented in Figures 1, 2A 
and 4 (ANOVA P=0.18). 
 
BRL37344 caused concentration-dependent increases in contractile force (Figure 1A 
and B). The intrinsic activity of BRL37344 with respect to (-)-isoprenaline (200 μM) in 
the groups of Figure 1 did not differ significantly (ANOVA, P=0.27) with an average of 
0.66±0.02 (n=34 trabeculae from 17 patients). The β1HAR and β2AR antagonist nadolol 
(200 nM) and β2AR antagonist ICI118,551 (50 nM) produced rightward shifts of the 
curve for BRL37344 (Figure 1A and B) by 1.9 log units and 0.9 log units (Table 2), 
respectively. The β3AR antagonist L-748,337 (1 μM) caused a 0.3 log rightward shift of 
the curve for BRL37344 (Figure 1A, Table 2). L-748,337 in the presence of nadolol did 
not cause further antagonism of the effects of BRL37344. The β1AR antagonist 
CGP20712A tended to cause a rightward shift of the curve for BRL37344 (Figure 1B) 
but it did not reach statistical significance (Table 2). Co-administration of ICI118,551 
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and CGP20712A caused a greater shift of the curve to BRL37344 than that induced by 
ICI118551 alone (Figure 1B, Table 2).  
 
The β3AR agonist SR58611 does not increase contractile force 
Inotropic results with SR58611 are shown in Figure 2A. The β3AR agonist SR58611 (1 
nM-10 μM) did not produce positive inotropic effects in the absence or presence of 
nadolol or L-748,337 at 37°C (Figure 2A). High SR58611 concentrations tended to 
reduce force in the presence of nadolol but the effects of the highest concentration used 
(10-5M) were not significant (P=0.14 IBMX vs nadolol; P=0.12 IBMX + L748337 vs 
IBMX + nadolol + L748337). 
 
Stable (-)-CGP12177-evoked contractions are decreased by (-)-bupranolol but not by 
L-748,337  
Human right atrial trabeculae were incubated with nadolol to block β1HAR and β2AR, 
and IBMX was used to enhance the contractile effects of (-)-CGP12177 (Skeberdis et 
al., 2008). Figure 3A illustrates the results from a representative experiment and Figure 
3B shows a summary of the results. IBMX (10 μM) slightly increased trabecular force 
after 30 min (basal 4.13 ± 0.49 mN, IBMX 5.92 ± 0.79 mN, n = 24 trabeculae, four 
patients, P < 0.0001). The effect of IBMX remained stable for 1 h but faded by the 90th 
min of exposure. (-)-CGP12177 (200 nM) caused a stable increase in force which was 
significantly reduced by the addition of (-)-bupranolol (1 μM) but not affected by the 
addition of L-748,337 (1 μM), (P = 0.001, one-way ANOVA, Figure 3B). Results of 
trabeculae obtained from 4 patients demonstrate that L-748,337 did not affect the 
response to (-)-CGP12177 (P = 0.12), inconsistent with the effect of  (-)-CGP12177 
being mediated through β3AR. In contrast, (-)-bupranolol reduced the response to (-)-
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CGP12177 by 91 ± 16%, n = 4, P = 0.002 (Figure 3B), consistent with it being 
mediated through β1LAR, as observed before on human atrium (Kaumann, 1996) and 
with recombinant β1AR (Joseph et al., 2004). 
 
L-748,337 does not modify the contractile potency of (-)-CGP12177  
Conceivably, the lack of antagonism by L-748,337 of the inotropic response to (-)-
CGP12177 could be due to firm binding of (-)-CGP12177 to β3AR. We therefore 
investigated whether the β3AR occupancy caused by a 30 min pre-incubation of the 
atrial trabeculae with L-748,337 could prevent the inotropic effects of (-)-CGP12177. 
However, cumulative concentration-effect curves for (-)-CGP12177 in the presence of 
nadolol (200 nM) and IBMX (10 μM) were not shifted to the right by preincubation 
with L-748,337 (1 μM) (Figure 4), indicating the response is not mediated through 
β3AR. The -logEC50M values of (-)-CGP12177 in the absence and presence of L-
748,337 were 7.21±0.09 and 7.41±0.13, respectively (data from 25 trabeculae from 8 
patients, P=0.2). 
 
ICa-L responses to BRL37344, SR58611 and (-)-CGP12177 at 24°C   
ICa-L responses to the agonists in the presence of nadolol (200 nM) at 24°C are shown in 
Figure 5. Similar to the findings of Skeberdis et al. (2008), BRL37344 and SR58611 
increased ICa-L and the responses were prevented by L-748,337, consistent with 
mediation through β3AR. The responses to BRL37344 (1 μM) were (% over basal): 
29.4±9.1% (range –10.7-94.7%), n=14/9 myocytes/patients (P=0.01, paired t-test). The 
responses to SR58611 (1 μM) were: 21.1±10.0% (range: from -4.8 to 217.6%), n=22/8 
(P=0.034). 
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(-)-CGP12177 (1 μM) also increased ICa-L. This effect was not observed when β1LAR 
was blocked with (-)-bupranolol (Figure 5). However, L-748,337 did not prevent the 
response to (-)-CGP12177. Our results therefore indicate mediation of the response to  
(-)-CGP12177 through β1LAR but not β3AR. The response to (-)-CGP12177 was  
34.5±10.8% (-3.9-151.9%) n=18/7 (P=0.002). For comparison, the response to (-)-
isoprenaline (1 μM) was 289.6±57.9% (90.0-705.0%) n=10/5 (P=0.00002).  
 
BRL37344 and SR58611 do not increase ICa-L at 37°C 
BRL37344 and SR58611 did not affect ICa-L responses at 37°C in the absence or 
presence of IBMX (Figure 6). (-)-Isoprenaline (1 μM) in the absence of IBMX 
increased ICa-L to 344.±34.3 (160-530%) over basal (n=13/9 P=0.00002). 
    
Antagonism of (-)-CGP12177-evoked increase in ICa-L by (-)-bupranolol but not by L-
748,337 at 37°C  
The effect of (-)-CGP12177 on ICa-L responses at 37°C are shown in Figure 7. (-)-
CGP12177 (1 µM) did not affect ICa-L while (-)-isoprenaline caused a 4-fold increase. 
However, in the presence of IBMX, which caused a small increase of ICa-L, (-)-
CGP12177 elicited a further increase in ICa-L. The response to IBMX (% over basal) was 
21.8±9.4% (-12.5-131.3%) n=20/9 (P=0.037) and that to (-)-CGP12177 (as % of 
IBMX) was 31.4±10.0% (-14.2-124.1%) (P=0.015). The response to (-)-CGP12177 was 
resistant to blockade by ICI118,551 and L-748,337 but prevented by (-)-bupranolol. 
During blockade of β1HAR and β2AR with nadolol (200 nM) (-)-CGP12177 caused an 
increase of ICa-L in the presence of IBMX that was prevented by (-)-bupranolol but 
resistant to blockade by L-748,337. The response to IBMX in the presence of nadolol 
(200nM) was 9.3±4.8% over basal (-16.4-39.1%) n=13/5 (P=0.04). The response to (-)-
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CGP12177 in the presence of both nadolol and IBMX (as % over IBMX) was 16.8±8.2 
% (0-103.1%) (P=0.027). The responses to (-)-CGP12177 in the presence of IBMX 
were not different in the absence and presence of nadolol (P=0.3). Responses to (-)-
CGP12177 in the presence of IBMX did not significantly differ from the corresponding 
responses in the presence of ICI118,551 or L-748,337. Taken together, these results are 
consistent the ICa-L responses to (-)-CGP12177 being mediated through β1LAR, but not 
β1HAR, β2AR or β3AR.  
 
BRL37344 and SR58611 do not increase atrial force at 24°C 
To investigate whether the small increases in ICa-L, evoked by BRL37344 and SR58611, 
that can be inhibited by L-748,337, are inotropically relevant we studied their effects at 
24°C in the presence of nadolol (200 nM), in the absence and presence of IBMX. 
BRL37344 (Figure 1C) and SR58611 (Figure 2B) failed to increase contractility under 
these conditions. In the presence of nadolol high SR58611 concentrations tended to 
reduce force in the absence but not presence of IBMX, but the effects of the highest 
concentration used (10-5M) were not significant (P=0.13). 
 
(-)-CGP12177-evoked increases in atrial force at 24°C are antagonized by (-)-
bupranolol but not by L-748,337.  
We also investigated whether the increase in ICa-L observed with (-)-CGP12177 in the 
presence of IBMX at 24°C is also translated into a positive inotropic effect (Figure 8). 
Nadolol (200 nM), used to block β1HAR and β2AR, decreased contractile force, 
probably as an inverse agonist. Since the positive inotropic effects to (-)-CGP12177 
tend to fade (Kaumann, 1996; Kaumann et al., 2007) due to phosphodiesterase activity, 
and to amplify possible force responses (Kaumann and Molenaar, 1997; Kaumann et al., 
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2007), IBMX (10 μM) was administered. IBMX increased force until a plateau ensued, 
on which cumulatively increasing (-)-CGP12177 concentrations were administered. (-)-
CGP12177 caused concentration-dependent decreases of force at low concentrations 
followed by marginal increases in force at high concentrations. Pre-incubation with L-
748,337 (1 μM) for 30 min before the IBMX administration did not affect the 
cardiodepressant or cardiostimulant effects of (-)-CGP12177 (Figure 8A).  
 
The full inverse agonist (-)-propranolol (Chidiac et al., 1994) abolishes the inverse 
agonist activity of (-)-CGP12177 at ICa-L in the presence of IBMX in murine ventricular 
myocytes (Freestone et al., 1999). Therefore, to prevent the inverse agonist activity and 
uncover agonist activity of (-)-CGP12177 we used (-)-propranolol. As expected from a 
robust inverse agonist, (-)-propranolol decreased contractile force significantly more 
than nadolol (Figure 8). (-)-CGP12177 produced positive inotropic effects in the 
presence of both IBMX and (-)-propranolol. L-748,337 did not antagonize the effects of 
(-)-CGP12177 but (-)-bupranolol (1 μM) caused a log unit rightward shift of the 
concentration-effect curve for (-)-CGP12177 (Figure 8B), consistent with mediation 
through β1LAR, but not β3AR. 
 
Discussion 
In the present work we provide evidence against the hypothesis that β3AR activation 
enhances human atrial contractility. The inotropic effects of BRL37344 were not 
mediated through β3AR but through β1AR/β2AR. BRL37344 and SR58611 caused 
small increases of ICa-L through β3AR at 24°C but not 37°C. The β3AR agonist SR58611 
did not modify atrial force. The increases of ICa-L at 24°C caused by BRL37344 and 
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SR58611were uncoupled from contractility. (-)-CGP12177 increased force and ICa-L at 
both 24°C and 37°C through β1LAR but not β3AR.  
  
Unlikelihood of positive inotropy through human atrial β3AR 
We confirmed the findings of Skeberdis et al. (2008) that BRL37344 increases atrial 
force in the presence of IBMX and nadolol. The β3AR-selective antagonist L-748,337 
(1μM) caused a small 2-fold rightward shift of the concentration-effect curve for 
BRL37344 (Figure 1A, Table 2). For the following reasons this shift is consistent with 
mediation of the effects of BRL37344 through β1AR and/or β2AR but not β3AR. The 
affinity (KD values) of L-748,337 for β1AR, β2AR and β3AR have been found to be 
(nM) 390, 204 and 2.8, respectively (Candelore et al., 1999). The expected log 
concentration-ratios (logCR) caused by the antagonist concentrations of receptor 
subtype-selective blockers used are compared with the theoretically expected logCR 
through the specific receptors (Table 1). The small antagonism of the effects of 
BRL37344 by L-748,337 is expected to result from an interaction with β1AR or β2AR, 
but not β3AR.  
 
The positive inotropic effects of BRL37344 in human atrial myocardium are 
antagonized by propranolol (Arch and Kaumann, 1993; Pott et al., 2003) and it has been 
suggested that BRL37344 acts through both β1AR and β2AR, plausibly mainly through 
the latter receptor (Arch and Kaumann, 1993). Nadolol caused a rightward shift of the 
concentration-effect curve for BRL37344 (Figure 1A, Table 2), indicating that its 
effects are mediated through β1AR/β2AR. The inotropic effects of BRL37344 shown by 
Skeberdis et al. (2008) in the presence of nadolol are consistent with the agonist 
surmounting the blockade of β1AR and β2AR by nadolol. The affinity estimate 
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(dissociation equilibrium constant Ki) of nadolol of 22 nM from recombinant β1AR, 
expressed at physiological density (Joseph et al 2004) and 59 nM for the receptors 
expressed at higher density (Baker, 2005), allows the prediction of a 0.6 to 1.0 log unit 
rightward shift with the nadolol concentration of 200 nM (Table 2) used by Skeberdis et 
al. (2008). As expected, our experiments depicted in Figure 1A demonstrate that the 
effects of BRL37344 are surmountably antagonized by 200 nM nadolol. However, the 
nadolol-induced shift of the concentration-effect curve was 1.0-1.3 log units greater 
than the expected 0.6-1.0 log unit shift (Table 2). This could be related to preferential 
activation of β2AR by BRL37344 in human atrium (Arch and Kaumann, 1993) and is 
supported by the 20-fold higher affinity of BRL37344 for recombinant β2AR compared 
to β1AR (Sennitt et al., 1998). Affinity estimates for nadolol for recombinant receptors, 
expressed at high density, reveal a 23-fold higher affinity of nadolol for β2AR than for 
β1AR (Baker, 2005). With a Ki = 2.5 nM for nadolol at β2AR (Baker, 2005) a 1.9 log 
unit shift of the concentration-effect curve for BRL37344 was expected and was 
experimentally observed, indicating interaction with β2AR (Table 2). A preferential 
activation of β2AR by BRL37344 is also supported by the greater antagonism of its 
inotropic effects in human atrial trabeculae by the β2AR-selective ICI118,551 compared 
to that induced by the β1AR-selective CGP20712A (Table 2). The increased 
antagonistic effect induced by co-administration of ICI118,551 + CGP20712A than by 
ICI118,551 alone (Figure 1B and C), suggests that BRL37344 activates β2AR at low 
concentrations and β1AR at high concentrations. 
 
SR58611 causes colon relaxation (Bianchetti and Manara, 1990; Kaumann and 
Molenaar, 1996) and lipolytic effects (Langin et al., 1991) through native β3AR, as well 
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as marked activation of adenylyl cyclase through recombinant β3AR (Blin et al., 1994). 
Skeberdis et al. (2008) reported a marginal increase in atrial force with SR58611 in the 
absence of IBMX but did not investigate this effect in the presence of IBMX. We did 
not observe any inotropic effects of SR58611 (1nM-10μM) in human atrium despite the 
presence of IBMX, which should have boosted the inotropic responses mediated 
through a cAMP-dependent pathway following βAR activation. This finding is in 
agreement with those of Bianchetti and Manara (1990) and Kaumann and Molenaar 
(1996) who were unable to show that SR58611 caused cardiostimulation in guinea-pig  
and rat atria, respectively.  
 
 
β1LAR but not β3AR mediate the positive inotropic effects and ICa-L responses to (-)-
CGP12177 in human atrium at 37°C 
The β3AR-selective blocker L-748,337 failed to antagonize the positive inotropic and 
ICa-L responses to (-)-CGP12177, which is inconsistent with their mediation through 
β3AR (Skeberdis et al., 2008). This together with our finding that (-)-bupranolol blocks 
both the increases in ICa-L and contractile force by (-)-CGP12177 in human atrial 
myocardium suggests that (-)-CGP12177 mediates these effects through β1LAR. 
 
Affinity estimates for the L-748,337-β3AR complex (-logKL = pKL) are available from 
recombinant human β3AR, transfected into CHO cells (pKL=8.40, (Candelore et al., 
1999)) and from human β3AR of detrusor muscle (pKL=7.65, (Wuest et al., 2009)). 
Knowing the KL of L-748,337, the concentration-ratio (CR) of equieffective (-)-
CGP12177 concentrations in the presence and absence of L-748,337 can be calculated 
from CR=1+[L-748,337]/KL, where KL is the equilibrium dissociation constant of L-
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748,337 for the β3AR. Using 22 nM (from the pKL=7.65) as the equilibrium 
dissociation constant (Wuest et al., 2009) and assuming that L-748,337 and (-)-
CGP12177 compete for the same β3AR population, 1 μM L-748,337 would cause a CR 
of 46.5, equivalent to a 1.67 log unit rightward shift of the concentration-effect curve 
for (-)-CGP12177 (broken line of Figure 4). However, 1 μM L-748,337 did not change 
the concentration-effect curve and potency (-logEC50M) of (-)-CGP12177, ruling out 
mediation through β3AR. Moreover, L-748,337 did not significantly reduce the effects 
of (-)-CGP12177 in our kinetic experiments (Figure 3). Instead, (-)-bupranolol 
antagonized the effects of (-)-CGP12177 (Figure 3), as previously observed with human 
atrial (Kaumann, 1996; Kaumann and Molenaar, 2008) and recombinant β1AR (Joseph 
et al., 2004), indicating mediation through β1LAR (Kaumann and Molenaar, 2008). 
Furthermore, (-)-bupranolol also prevented the small increase in ICa-L caused by (-)-
CGP12177, as expected from mediation through β1LAR. The consistency of moderate 
inotropic and ICa-L responses to (-)-CGP12177 suggests that the intropic effect is 
triggered by increased Ca2+ release from the sarcoplasmic reticulum as a result of 
increased ICa-L (Bers, 2002). Our results agree with the persistence of cardiostimulant 
effects of (-)-CGP12177 and blockade by (-)-bupranolol in β3AR-knockout mice 
(Kaumann et al., 1998). 
 
(-)-CGP12177-evoked increases in ICa-L are mediated through β1LAR at both 24°C and 
37°C 
Skeberdis et al. (2008) demonstrated, in human atrial cardiomyocytes at room 
temperature (19-25°C), that BRL3744, SR58611 and CGP12177 induced an increase in 
ICa-L which was antagonized by 1 μM L-748,337, suggesting mediation through β3AR. 
We confirmed that the 3 agonists increased ICa-L at 24°C and that L-748,337 
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antagonized the effects of BRL37344 and SR58610. However, we found that the (-)-
CGP12177-evoked ICa-L responses were resistant to blockade by L-748,337 but 
antagonized by (-)-bupranolol, ruling out the involvement of β3AR, but indicating 
mediation through β1LAR. We do not know the reason for the discrepancy between our 
results and those of Skeberdis et al. (2008). Inspection of Figure 2 of Skeberdis et al. 
(2008), which compares the blockade by L-748,337 of the ICa-L responses to BRL37344 
and CGP12177, reveals that the onset kinetic of the response to BRL37344 after 
washout of L-748,337 was conspicuously slower than the onset kinetic of BRL37344 
before the L-748,337 exposure. The slow onset response to BRL37344 after washout of 
L-748,337 is presumably due to the time it takes for the antagonist to dissociate from 
the β3AR. One would expect a similar delay for the onset kinetics of CGP12177 after 
washout of L-748,337. Surprisingly, however, for unknown reasons the onset kinetics of 
CGP12177, before and after L-748,337, were virtually identical. Unfortunately, these 
puzzling kinetic differences between BRL37344 and CGP12177 and the antagonism by 
L-748,337 were not discussed (Skeberdis et al., 2008). 
 
In our study, (-)-CGP12177 did not appear to affect ICa-L at 37°C when added alone but 
small significant increases of ICa-L were observed in the presence of IBMX. L-748,337 
(1 µM) did not prevent these responses to (-)-CGP12177, indicating that β3AR are 
unlikely to be involved, but    (-)-bupranolol blocked the responses, confirming their 
mediation through β1LAR (Figure 7). These results suggest that at physiological 
temperature phosphodiesterases hydrolyse sufficient cAMP, generated through β1LAR 
stimulation, to blunt PKA-catalysed phosphorylation of the L-type Ca2+ channel. We 
reported previously that inhibition of phosphodiesterases with IBMX facilitates the 
appearances of small (-)-CGP12177-evoked ICa-L responses (equivalent to 19% of the 
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response to (-)-isoprenaline) on murine ventricular cardiomyocytes (Freestone et al., 
1999). 
 
Human atrial β2AR mediate robust increases in ICa-L at room temperature (Skeberdis et 
al., 1997) and there is evidence for agonist effects of racemic CGP12177, mediated 
through recombinant β2AR (Pak and Fishman, 1996) and (-)-CGP12177 in human β2AR 
overexpressed in the hearts of TG4 mice (Heubach et al., 2003). However, the β2AR-
selective antagonist ICI118,551 failed to antagonize the (-)-CGP12177-evoked ICa-L 
response, therefore ruling out a contribution of β2AR under our conditions at 37ºC. 
 
The β3AR-mediated ICa-L responses to BRL37344 and SR58611 at 24ºC are uncoupled 
from the contractile machinery  
We confirmed that at 24ºC BRL37344 and SR58611 evoke a β3-AR-mediated increase 
of ICa-L in myocytes. These β3-AR-mediated increases of ICa-L were surprisingly small 
compared to the effect of non-selective β-AR-stimulation with (-)-isoprenaline (Figure 
5). It should be noted that the size of the agonist effects on ICa-L reported by Skeberdis et 
al. (2008) differed widely between 136±21% and 45±6% increase over basal, of which 
we could only confirm the latter estimate. We therefore investigated whether the small 
increases in ICa-L are translated into contractile responses at 24°C. Our results with atrial 
trabeculae at 24ºC in the presence of nadolol failed to uncover any inotropic effects of 
BRL37344 and SR58611 (1nM-10μM, Figure 2B), not even in the presence of the 
phosphodiesterase inhibitor IBMX. The lack of inotropic response to BRL37344 and 
SR58611 could be related to the small magnitude of the ICa-L response at 24ºC (10 and 
7% respectively of the (-)-isoprenaline response), or to an inherent inability of the β3AR 
to produce the coupling messages necessary to activate the contractile machinery. For 
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either situation, the enhanced activation of ICa-L through β3AR appears to be unable to 
stimulate Ca2+-induced Ca2+ release from the RyR2 channels of the sarcoplasmic 
reticulum (Bers, 2002; Fabiato, 1983), thereby preventing an increase in atrial 
contractility. 
 
It could be argued that phylogenetically β3AR may have had a particular role in brown 
adipose tissue to generate heat under cold circumstances in rodents but largely lost in 
humans (reviewed in Arch, 2008). Human β3AR share only 40-50% of the amino acids 
with β1AR and β2AR, consistent with early divergence during evolution (Granneman et 
al., 1993). Interestingly, increased mRNA of β1AR, β2AR and especially β3AR, as well 
as increased left ventricular ejection responses to isoprenaline have been reported in the 
hearts of hibernating bears compared to active bears (Nelson et al., 2010). We therefore 
also investigated the inotropic effects of BRL37344 at 24ºC. However, as found with 
SR58611, BRL37344 also did not reveal a vestige of β3AR-mediated contractile 
responses at 24ºC.  
 
In contrast to the effects at 37ºC, at 24ºC BRL37344 did not augment force through 
β1HAR and β2AR but (-)-isoprenaline and (-)-CGP12177 still increased force at 24ºC.  
These findings suggest that the low temperature blunts the inotropic message caused by 
the partial agonist BRL37344 but still allows the full agonist (-)-isoprenaline to produce 
robust increases in force through β1HAR and β2AR. Since (-)-CGP12177 still increased 
force at 24ºC, it appears that positive inotropic responses are less attenuated by low 
temperature through β1LAR than the responses to the partial agonist BRL37344 through 
β1HAR and β2AR.  
.  
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Relationship between ICa-L responses and inotropic responses to (-)-CGP12177 at 24ºC 
We have demonstrated that at 37ºC the small ICa-L responses correlate with the moderate 
inotropic responses to (-)-CGP12177, both mediated through β1LAR under our 
conditions of PDE inhibition with IBMX. The inotropic relevance of the β1LAR-
mediated increase in ICa-L at 24ºC is, however, not clear. (-)-CGP12177 only produced 
marginal increases of contractile force in the presence of nadolol. We attempted to 
uncover (-)-CGP12177-evoked increases in force by inhibiting phosphodiesterase with 
IBMX. However, low (-)-CGP12177 concentrations in the presence of both nadolol and 
IBMX caused concentration-dependent negative inotropic effects, higher concentrations 
tended to increase contractile force (Figure 8). These cardiodepressant effects and 
marginal cardiostimulant effects of (-)-CGP12177 were not significantly modified by L-
748,337 and appear therefore unrelated to β3AR (Figure 8). We attribute the negative 
inotropic effects of (-)-CGP12177 to inverse agonism via β1AR, as previously observed 
on murine ventricular ICa-L at room temperature. Under these conditions  (-)-CGP12177 
was an inverse agonist in the presence of IBMX, but increased ICa-L (Freestone et al., 
1999) in the presence of the efficacious inverse agonist (-)-propranolol (Chidiac et al., 
1994). We suspected that the marginal positive inotropic responses to higher (-)-
CGP12177 concentrations were probably mediated through β1LAR. As previously 
observed with murine ICa-L responses to (-)-CGP12177 (Freestone et al., 1999), (-)-
propranolol abolished the negative inotropic effects and facilitated positive inotropic 
effects of (-)-CGP12177. These positive inotropic effects of (-)-CGP12177 in the 
presence of (-)-propranolol and IBMX were antagonized by (-)-bupranolol but not L-
748,337, consistent with the ICa-L responses to (-)-CGP12177 being mediated through 
β1LAR but not β3AR (Figure 8). 
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Although the small ICa-L responses to (-)-CGP12177 through β1LAR as well as 
BRL37344 and SR58611 through β3AR at 24ºC were not significantly different 
(P=0.39), only activation of the β1LAR, but not β3AR, enhanced contractility. However 
there is a caveat, unlike the ICa-L responses to the three agonists, which could be elicited 
in the absence of IBMX, a special condition containing not only IBMX but also (-)-
propranolol (to prevent (-)-CGP12177-evoked inverse agonism) was necessary to 
demonstrate small concentration-dependent increases in atrial contractility with (-)-
CGP12177. Nevertheless at 24ºC, β1LAR but not β3AR, appear to activate mechanisms 
leading to enhanced contractility. Thus, excitation-contraction coupling was receptor-
dependent but not temperature-dependent. 
 
Conclusions We provide strong evidence against the hypothesis that β3AR activation 
increases human atrial contractility. Increases in human atrial force by BRL37344 and  
(-)-CGP12177 are mediated through β2AR>β1AR and β1LAR, respectively. The β3AR 
agonist SR58611 did not increase atrial force. Small β3AR-mediated increases in ICa-L 
by BRL37344 and SR58611 become apparent only at low non-physiological 
temperatures but appear uncoupled from contractility. The inotropic and ICa-L responses 
to (-)-CGP12177 are mediated through the low affinity site of the β1AR, β1LAR , at both 
24ºC and 37ºC. The lack of human atrial responses through β3AR demonstrated with  
(-)-CGP12177, BRL37344 and SR58611, suggests that therapeutically beneficial β3AR 
agonists, such as mirabegron for overactive bladder (Michel et al., 2010), do not pose a 
risk to cardiac function.  
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Table 1 Characteristics of the patients 
             
     
             
n          139   
Gender, m/f         104/35   
Age, years          68±0.8 
BMI, kg m-2         27.6±1   
CAD, n         110   
AVD/MVD, n         29   
CAD+AVD/MVD, n        20 
Hypertension, n        99   
Diabetes, n         34   
Hyperlipidaemia, n        73  
LVEF, %         52±1.2  
Cardiovascular medication, n 
Digitalis         6   
ACE inhibitors/AT1-blockers      79  
β-blockers         104   
  Metoprolol       67 
  Bisoprolol       27 
  Carvedilol       5 
  Nebivolol       1 
Calcium channel blockers       29 
Diuretics         15   
Nitrates         28   
Lipid-lowering drugs        67  
             
CAD=coronary artery disease; AVD=aortic valve disease; MVD=mitral valve disease; 
LVEF=left ventricular ejection fraction; ACE=angiotensin-converting enzyme; 
AT=angiotensin receptor. 
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Table 2 Effects of antagonists on the inotropic potency of BRL37344 in the 
presence of IBMX (10 μM) 
 
 n -LogEC50 (M)   LogCR 
    observed  expected 
Control (no antagonist) 32/17 6.82±0.11 --   -- 
CGP20712A (300 nM) 5/4 6.44±0.10 0.38   2.28a (β1H) 
ICI118,551 (50 nM) 4/4 5.96±0.18** 0.86   1.72a (β2) 
CGP20712A + ICI118,551 5/4 4.61±0.28** 2.21   --  (β1H+β2) 
L-748,337 ( 1µM) 22/8 6.49±0.11** 0.33   0.55b (β1H) 
        0.77b (β2) 
        1.67c (β3) 
        2.55b (β3) 
Nadolol (200 nM) 8/6 5.13±0.10*** 1.69   1.02d    (β1H) 
        0.64e    (β1H) 
        1.91e (β2) 
Nadolol + L-748,337  10/6 5.10±0.09*** 1.72   --  
n = Trabeculae/patients 
*P<0.05, ** P <0.01, *** P <0.001*** compared to control 
a Kaumann and Lemoine, 1987 
b Candelore et al., 1999 
c Wuest et al., 2009 
dJoseph et al., 2004 
e Baker, 2005 
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Figure 1 Mediation of the positive inotropic effects of BRL37344 through β1AR/β2AR 
but not β3AR in human atrial trabeculae. (A) Cumulative concentration-effect curves 
were carried out in the presence of IBMX (10 μM) for BRL37344 in the absence and 
presence of nadolol (200 nM, β1HAR/β2AR antagonist), L-748,337 (1 μM, β3AR 
antagonist) or nadolol + L-748,337. (-)-Isoprenaline (200 µM), administered after a 
steady state response to 200 µM BRL37344, increased force (% over IBMX) by 
284±42.7%. (B) Curves for BRL37344 were also determined in the absence and 
presence of ICI118,551 (50 nM, β2AR-selective antagonist, ICI) or CGP20712A (300 
nM, β1HAR-selective antagonist) or co-administration of ICI118,551 + CGP20712A. (-
)-Isoprenaline (200 µM), administered after a steady state response to 60 µM 
BRL37344, increased force (% over IBMX) by 312±63.5%. Antagonists were incubated 
for at least 45 min before a curve for an agonist was started. Nadolol was incubated for 
15 min, followed by the additional administration of L-748,337 for 30 min, followed by 
the administration of IBMX (10 μM) for 15 min before a curve was begun. (C) Lack of 
inotropic effects of BRL37344 at 24ºC. At 24ºC  (-)-isoprenaline and Ca2+ (8 mM) 
increased force (mN) from a basal of 5.2±0.9 to 10.8±1.5 and 13.3±2.1 respectively (n = 
28/4). At 37ºC (-)-isoprenaline and Ca2+ increased force (mN) from a basal level of 
7.6±0.6 to 12.7±0.7 and 13.5±0.7 respectively (n = 86/17). 
 
Figure 2 Lack of positive inotropic effects of SR58611 at 37ºC and 24ºC in human 
atrial trabeculae. (A) Cumulative concentration-effect curves at 37ºC were carried out 
for SR58611 in the absence and presence of nadolol (200 nM, β1HAR/β2AR antagonist) 
or L-748,337 (1 μM, β3AR antagonist) or nadolol + L-748,337, each curve in the 
presence of IBMX (10 μM). (B) Curves for SR58611 at 24ºC carried out in the absence 
or presence of nadolol, nadolol +  L-748,337, or nadolol + IBMX, or IBMX + nadolol + 
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L-748,337. (-)-Isoprenaline (200 µM), administered after a steady state response to 10 
μM of SR58611, increased force (% over IBMX) at 37 ºC by 162±13.9 (% over IBMX, 
n=30). At 24 ºC the increase in force induced by (-)-isoprenaline (% over basal) in the 
absence and presence of IBMX was 767±152%, n=14/4 and 198±24%, n=30/4, 
respectively. Numbers in parentheses represent trabeculae/patient. At 24ºC  (-)-
isoprenaline and Ca2+ (8 mM) increased force (mN) from a basal value of 2.6±0.5 to 
6.3±0.8 and 6.8±0.7, respectively (n = 28/4). At 37ºC (-)-isoprenaline and Ca2+ increase 
force (mN) from a basal value of 5.5±1.0 to 10.6±1.5 and 11.3±1.5, respectively (n = 
28/4). 
 
 
Figure 3 (A) Mediation of the positive inotropic effects of (-)-CGP12177 through 
β1LAR but not β3AR. (-)-Bupranolol, but not L-748,337, reduced the increase in 
contractile force elicited by (-)-CGP12177 (200 nM) in the presence of IBMX (10 μM) 
and nadolol (200 nM). Representative and time-matched experiments in 6 trabeculae 
from the right atrial appendage of a 51 year old male patient undergoing coronary artery 
bypass grafting depicting the time course of the effects of IBMX (top trabeculum), of   
(-)-CGP12177 (second tracing), lack of antagonism by L-748,337 (1 μM) (third and 
fourth tracings) and blunting effect of (-)-bupranolol (1 μM) (bottom two tracings). 
Experiments were concluded by the addition of 200 μM (-)-isoprenaline (Iso) and 7 mM 
Ca2+ (final bath concentration 9.25 mM). Arrows indicate the addition of drugs. Bars 
indicate forces and time scale. (B) A summary of data from 24 trabeculae of 4 patients. 
A comparison of the contractile force obtained in the presence of 200 nM (-)-CGP 
12177 and after incubation of L-748,337, (-)-bupranolol or control was carried out by 
one-way ANOVA which indicated differences in cardiodepression (P = 0.001). Post-
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hoc tests revealed that (-)-bupranolol caused a reduction in contractile force, while there 
was no difference between control (marginal fade of (-)-CGP12177 contractile force 
over 50 min corresponding to the time of L-748,337 exposure) and L-748,337 (statistics 
indicated on the figure). 
 
 
Figure 4 L-748,337 does not change the inotropic potency of (-)-CGP12177 in the 
presence of nadolol (200 nM) and IBMX (10 μM). Concentration-effect curves for (-)-
CGP12177 in the absence and presence of L-748,337 (1 μM). Dotted concentration-
effect curve shows a theoretical curve for (-)-CGP12177 in the presence of L-748,337, 
expected to occur if L-748,337 antagonized the effects of (-)-CGP12177 at β3AR with 
pKB = 7.65. -LogEC50 values for (-)-CGP12177 in the absence (control) and presence 
for L-748,337 were 7.21±0.09 (13 trabeculae) and 7.41±0.13 (12 trabeculae), 
respectively, from 8 patients. (-)-Isoprenaline (200 µM) increased force by 511±103% 
over IBMX, n=25/8. Numbers in parentheses represent trabeculae/patients. 
 
Figure 5 L-748,337 (1 µM, L) prevents small ICa-L responses to SR58611 (1 µM, SR) 
and BRL37344 (1 µM, BRL) but not to (-)-CGP12177 (1 µM, CGP) at 24ºC in the 
presence of nadolol (200 nM, N). The responses to (-)-CGP12177 were prevented by    
(-)-bupranolol (10 μM, Bu). The ICa-L response to (-)-isoprenaline (1 µM, ISO) in the 
absence of nadolol is shown for comparison. Numbers in columns represent 
myocytes/patients. *P<0.05 compared to control (C).  
 
Figure 6 SR58611 (1µM, SR) and BRL37344 (1 µM, BRL), in the presence of nadolol 
(200 nM, N) fail to increase ICa-L in the absence and presence of IBMX (10 µM) at 37ºC. 
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The ICa-L response to (-)-isoprenaline (1 µM, ISO) in the absence of IBMX is shown for 
comparison.  Numbers in columns represent myocytes/patients.*P<0.05 compared to 
control (C). 
 
Figure 7 (-)-CGP12177 (1 µM, CGP) causes small increases of ICa-L at 37ºC, compared 
to (-)-isoprenaline (1 µM, ISO), in the presence but not absence of IBMX (10 µM) that 
are prevented by (-)-bupranolol (10 µM, BU) but not by L-748,337 (1 µM, L), 
ICI118,551 (50 nM, ICI) or nadolol (200 nM, N). * P<0.05 compared to the absence of 
IBMX. # P<0.05 compared to IBMX alone. Numbers in columns represent 
myocytes/patients. One arrow indicates agonist addition, two arrows indicate addition 
of IBMX followed by addition of (-)-CGP12177. C = control. 
 
Figure 8 Inotropic effects of (-)-CGP12177 at 24ºC. (-)-CGP12177 is a moderate 
inverse agonist in the presence of both nadolol (200 nM) and IBMX (10 μM) (A) but 
causes positive inotropic effects in the presence of both (-)-propranolol (200nM) and 
IBMX (10µM) through β1LAR but not β3AR (B). The effects of (-)-CGP12177 were 
resistant to blockade by L-748,337 (1 μM) but antagonized by (-)-bupranolol (1 μM). 
Antagonists were incubated for 45 min, followed by an additional administration of 
IBMX for 15 min before a concentration-effect curve for (-)-CGP12177 was carried out. 
Numbers in parentheses represent trabeculae/patients. (-)-Isoprenaline (200 µM), 
administered after a steady state response to the highest agonist concentration had been 
observed, increased force (% over IBMX) by 340±79%, n=15/6 in (A) and 947±202%, 
n=19/9 in (B). (-)-Isoprenaline and Ca2+ (8 mM) increased force (mN) from a basal 
value of 2.4±0.5 to 6.8±0.8 and 6.9±0.9, respectively (n = 34/8).  
 








